Product
Lanreotide Autogel
Aliases
lanreotide Autogel, Lanreotide autogel 120 mg
Name
lanreotide Autogel
2 clinical trials
1 drug
3 indications
Indication
AcromegalyIndication
Pancreatic TumorsIndication
Midgut Neuroendocrine TumoursDrug
lanreotideClinical trial
Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With MacroadenomaStatus: Completed, Estimated PCD: 2012-02-01
Clinical trial
Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 DaysStatus: Completed, Estimated PCD: 2019-10-16